首页|组织工程血管的研究进展

组织工程血管的研究进展

扫码查看
心血管疾病已成为全球死亡的主要原因,血管移植术(置换/搭桥)是临床上治疗严重心血管疾病的有效手段.然而,迄今为止,临床上尚无可以医用的小口径人工血管产品.组织工程血管(Tissue-Engineered Vascular Graft,TEVG)因具有良好的生物相容性,能够促进组织再生、宿主整合以及血管功能的实现而受到研究者的青睐.本文简述近年TEVG的研究进展,简要介绍制备技术、分析存在的缺陷和改进方向,以期为TEVG的研究发展提供参考.
Research progress of tissue-engineered vascular graft
Cardiovascular disease has become the leading cause of death worldwide.Vascular implantation(replacement/bypass)is an effective treatment for severe cardiovascular diseases in clinical practice.However,to date,there are no small diameters vascular grafts products available for medical use in clinical practice.Tissue-engineered vascular graft(TEVG)is favored by researchers due to their excellent biocompatibility,which can promote tissue regeneration,host integration,and the realization of vascular function.This article briefly describes the research progress of TEVG in recent years,including preparation techniques,analysis of existing defects,and improvement directions,in order to provide reference for the research and development of TEVG.

Cardiovascular diseaseVascular replacementVascular bypassVascular graftsTissue-engineered vascular graft

智登科、张靖爱、程曲汉、王恺、孔德领

展开 >

领博生物科技(杭州)有限公司,杭州 310018

南开大学生命科学学院,天津 300071

心血管疾病 血管置换 血管搭桥 人工血管 组织工程血管

国家重点研发计划

2023YFC2412400

2024

现代仪器与医疗
中国科学器材公司

现代仪器与医疗

影响因子:1.47
ISSN:2095-5200
年,卷(期):2024.30(4)
  • 1